TMC-114 (Tibotec) |
| |
| Authors: | Shurtleff Amy C |
| |
| Institution: | Department of Molecular Virology, United States Army Medical Research Institute for Infectious Diseases, Fort Detrick, MD 21702, USA. Amy.Shurtleff@DET.AMEDD.ARMY.MIL |
| |
| Abstract: | Tibotec (formerly Tibotec-Virco) is developing TMC-114 as a potential treatment for HIV-1 infection. In February 2001, TMC-126 was revealed as the series prototype, from which TMC-114 was developed. Because of its improved antiviral and superior pharmacokinetic properties, TMC-114 was selected for clinical development. Phase II trials of TMC-114 are underway. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
